Finding key to cancer drug Gleevec's limitations

University of Michigan researchers have developed an animal model that provides strong evidence why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukaemia survive longer, but does not keep the disease from returning if treatment ends...

Read the whole article on

More from